Substituted quinazolines

Details for Australian Patent Application No. 2009247793 (hide)

Owner Shire LLC

Inventors Franklin, Richard; Hirst, Kim; Golding, Bernard; Cicala, Peter

Agent Davies Collison Cave

Pub. Number AU-A-2009247793

PCT Pub. Number WO2009/138792

Priority 0808951.8 16.05.08 GB

Filing date 13 May 2009

Wipo publication date 19 November 2009

International Classifications

C07D 471/04 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups

A61K 31/519 (2006.01) - ortho- or peri-condensed with heterocyclic rings

A61P 7/02 (2006.01) Drugs for disorders of the blood or the extracellular fluid

C07D 475/04 (2006.01) Heterocyclic compounds containing pteridine ring systems

C07D 491/048 (2006.01) Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or

C07D 495/04 (2006.01) Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms

Event Publications

9 December 2010 PCT application entered the National Phase

  PCT publication WO2009/138792 Priority application(s): WO2009/138792

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009247794-Substituted quinazolines as blood platelet lowering agents

2009247792-2Hpyrimido [2, 1-B] quinaz0lin-2-0ne derivatives and their use as platelet anti-aggregative agents